1983984-04-8
1983984-04-8
Chemical Structure
Avotaciclib sulfate
Synonym(s): BEY1107 sulfate
- CAS. Nr.: 1983984-04-8
- Formula:C13H13N7O5S
- Molecular Weight:379.35
InChIKey: SOYPPDFOEBVLDG-UHFFFAOYSA-N
SMILES: OC1=CC=C(C2=NC(N)=NC=C2)N=C1C3=NC(N)=NC=C3.O=S(O)(O)=O
Biological Activity: Avotaciclib (BEY1107) sulfate is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib sulfate can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib sulfate can be used in the research of cancer such as pancreatic cancer and lung cancer[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Avotaciclib sulfate | Avotaciclib (BEY1107) sulfate is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib sulfate can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib sulfate can be used in the research of cancer such as pancreatic cancer and lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232.
- [2]. Zhang L, et al. Suppression of cyclin-dependent kinase 1 synergizes with checkpoint kinase 2 inhibitor to promote death of non-small cell lung cancer cells with radiotherapeutic resistance. Journal of Radiation Research and Applied Sciences, 2024, 17(2): 100900.
Keywords
